Panel seems to like Novartis drug
An FDA panel officially reviews an experimental Novartis psoriasis medication Monday, but Reuters notes that preview documents on the FDA's website indicate members consider secukinumab an approvable anti-inflammatory.
The FDA does not have to follow a panel's recommendations (as seen in the approval of the pain medication Zohydro) but often does.
A secukinumab approval would do more than merely give Novartis another product to market. Reuters notes that the drug is a member of a class of drugs known as IL-17 inhibitors, which have “shown unprecedented success in plaque-psoriasis, the most common form of the painful skin condition.”